Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA4 | P22748 | 2/20 | 0.59 |
| ▸ | CA6 | P23280 | 2/20 | 0.59 |
| ▸ | CA5A | P35218 | 2/20 | 0.59 |
| ▸ | CA7 | P43166 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.59 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | TTR | P02766 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5898485 | 1.00 | HCAR2 (0.74) | HCAR2LMNACA12CA4CA6 | |
| SCHEMBL5897892 | 1.00 | HCAR2 (0.74) | HCAR2LMNACA12CA4CA6 | |
| Ammonia Solution, Strong SCHEMBL27556861 | 0.98 | HCAR2 (0.72) | HCAR2LMNACA12CA4CA6 | |
| SCHEMBL28081360 | 0.92 | HCAR2 (0.63) | HCAR2LMNACA12CA4CA6 | |
| SCHEMBL357565 | 0.91 | HCAR2 (0.89) | HCAR2LMNACA12CA4CA6 | |
| SCHEMBL337503 | 0.91 | HCAR2 (0.89) | HCAR2LMNACA12CA4CA6 | |
| SCHEMBL337504 | 0.91 | HCAR2 (0.89) | HCAR2LMNACA12CA4CA6 | |
| SCHEMBL28388377 | 0.89 | LMNA (0.79) | HCAR2LMNACA12CA4CA6 | |
| SCHEMBL17695763 | 0.89 | HCAR2 (0.59) | HCAR2LMNACA12CA4CA6 | |
| SCHEMBL27659194 | 0.89 | HCAR2 (0.85) | HCAR2LMNACA12CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049444-B2 | Monomethyl fumarate precursor drug compounds and pharmaceutical compositions thereof | AGATHONBIO CO., LTD. (KR) | 2024-07-30 | — | — | US | claimed |
| US-12049444-B2 | Monomethyl fumarate precursor drug compounds and pharmaceutical compositions thereof | AGATHONBIO CO., LTD. (KR) | 2024-07-30 | — | — | US | disclosed |
| US-6984648-B2 | Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| EP-1427408-A4 | CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-$g(a) CONVERTING ENZYME (TACE) | BRISTOL MYERS SQUIBB CO (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040162426-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | LU ZHONGHUI (US) | 2004-08-19 | — | — | US | disclosed |
| EP-1427408-A2 | CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-$g(a) CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6743807-B2 | TREATMENT OF RHEUMATOID AND OSTEOARTHRITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, TUMOR METASTASIS OR INVASION, PERIODONTAL DISEASE AND BONE DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-6740649-B2 | ANTIINFLAMMATORY AGENTS; OSTEOPOROSIS | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-25 | — | — | US | disclosed |
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-07-24 | — | — | US | disclosed |
| WO-2003024899-A2 | CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-03-27 | — | — | WO | disclosed |
| EP-1263755-A2 | CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-07 | — | — | US | disclosed |
| WO-2001070673-A2 | CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-0031997-B2 | POLYMERISATION PROCESS FOR PRODUCTION OF POLYMER MICROPARTICLES OF HIGH REFRACTIVE INDEX AND COATING COMPOSITIONS CONTAINING THEM | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-09-14 | — | — | EP | disclosed |
| US-4427820-A | STYRENE, MALEIC ACID DERIVATIVE, EMULSION POLYMERIZATION | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-01-24 | — | — | US | disclosed |
| EP-0031997-B1 | POLYMERISATION PROCESS FOR PRODUCTION OF POLYMER MICROPARTICLES OF HIGH REFRACTIVE INDEX AND COATING COMPOSITIONS CONTAINING THEM | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-12-28 | — | — | EP | disclosed |
| EP-0031997-A1 | Polymerisation process for production of polymer microparticles of high refractive index and coating compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | RNPEP, TNF, ANPEP | HCAR2 1090/4885LMNA 2122/4885CA12 573/4885 |
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAMTS1, MMP1, ADAM17 | HCAR2 191/4885LMNA 1599/4885CA12 61/4885 |
| US-20040162426-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | RNPEP, TNF, ANPEP | HCAR2 1090/4885LMNA 2122/4885CA12 573/4885 |
| US-12049444-B2 | Monomethyl fumarate precursor drug compounds and pharmaceutical compositions thereof | FH, FPGS, FAH | HCAR2 882/4885LMNA 4154/4885CA12 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.